Furthermore, combining poly (ADP-ribose) polymerase (PARP) and WEE1 inhibitors has shown promising activity in p53abn/CCNE1-amplified serous carcinomas, targeting the specific DNA damage response vulnerabilities created by these alterations [81,116,117,118,119]. This evidence concerns the gene WEE1 and serous adenocarcinoma.